CytRx Logo Vector
CytRx Corporation is a clinical-stage biopharmaceutical company developing novel anti-inflammatory therapeutics for a variety of diseases, including arthritis, inflammatory bowel disease (IBD), and non-alcoholic steatohepatitis (NASH). The company's lead product candidate, semagacestat, is a potent and selective inhibitor of p38 MAP kinase, an enzyme that plays a key role in inflammation. CytRx has also developed a pipeline of other anti-inflammatory drugs, including CRX-104 and CRX-302.